ERBB2 and neoplasm: Current NCCN guidelines recommend adjuvant chemotherapy and targeted therapy for T1c human epidermal growth factor receptor (HER)2-positive and triple-negative tumours, and, increasingly, more women with T1b tumours are also receiving this treatment.